Skip to content
Screener

Corcept Therapeutics CORT Shares (Diluted)

Shares (Diluted) at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
172.8M+8.4%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
104.1M+11.8%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
58.3M+36.5%
Immunome logo
ImmunomeIMNM
113.1M+42.5%
Arcus Biosciences logo
Arcus BiosciencesRCUS
126.1M+18.4%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
24.7M+75.9%

Other financials

Income statement

See full
Revenue$256.1M+31.7%
Gross profit$252.1M+32.0%
Operating income$41.3M+54.8%
Net income$43.0M+22.3%
EPS (diluted)$0.36+24.1%

Balance sheet

See full
Cash & equivalents$112.3M+9.3%
Total debt$9.4M+42.6%
Total equity$705.8M+11.0%
Total assets$888.7M+10.8%

Cash flow

See full
Operating cash flow$33.5M-23.7%
CapEx$2.5M+4,335%
Free cash flow$31.0M-29.3%

Valuation

See full
Market cap$11.67B+57.0%
Enterprise value$11.57B+57.7%
P/E211.5×+156×
P/S14.1×+3.7×

Profitability

See full
Gross margin98.3%-0.1pp
Operating margin0.8%-13.5pp
Net margin6.6%-12.0pp
FCF margin12.9%-12.3pp

Returns & leverage

See full
Return on equity8.2%-13.5pp
Debt / equity0.0×
Current ratio2.9×-0.2×

Where this comes from

Reported directly by Corcept Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-050613
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Income tax (expense) benefit(2,944)3,45710,01014,386
Net income42,98735,14911,22655,696
Net income attributable to common stockholders42,14134,61111,01754,918
Basic net income per common share$0.40$0.33$0.11$0.53
Diluted net income per common share$0.36$0.29$0.09$0.46
Weighted-average shares outstanding used in computing net income per common share
Basic105,377104,111104,909104,108
Diluted118,385120,485116,373120,227

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Corcept Therapeutics's shares (diluted)?
Corcept Therapeutics (CORT) reported shares (diluted) of 118.4M in Q2 2026.
How has Corcept Therapeutics's shares (diluted) changed year-over-year?
Corcept Therapeutics's shares (diluted) decreased by 1.7% year-over-year, from 120.5M to 118.4M.
What is the long-term trend for Corcept Therapeutics's shares (diluted)?
Over 4 years (2021 to 2025), Corcept Therapeutics's shares (diluted) has grown at a -1.4% compound annual growth rate (CAGR), from 507.4M to 479.7M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Corcept Therapeutics's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude